Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$73.43 USD

73.43
684,127

+0.80 (1.10%)

Updated Jul 22, 2024 04:00 PM ET

After-Market: $73.40 -0.03 (-0.04%) 4:30 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 43% (143 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Inspire Medical's (INSP) Inspire Therapy Gets CE Mark Approval

by Zacks Equity Research

Inspire Medical's (INSP) receipt of the latest CE mark certification will likely enable it to continue to deliver Inspire products globally.

Globus Medical (GMED) Global Sales, Innovation Aid Growth

by Zacks Equity Research

In line with the company's business strategy to focus on its integrated product development, Globus Medical (GMED) is consistently making efforts in research and development.

Intuitive Surgical (ISRG) Q2 Earnings Beat, Procedures Robust

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter results reflect a healthy demand for procedures. Higher pricing boosts procedure sales. An improvement in margins buoys well.

Intuitive Surgical (ISRG) Gains 26% Year to Date: Here's Why

by Zacks Equity Research

Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.

Abbott (ABT) Q2 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.

Globus Medical (GMED) Gets FDA Nod for ExcelsiusFlex, ACTIFY 3D

by Zacks Equity Research

Globus Medical (GMED) gets the FDA 510(k) clearance for its ExcelsiusFlex with Total Knee Arthroplasty application and ACTIFY 3D Total Knee System.

Is QIAGEN (QGEN) a Good Investment Now? Key Factors to Note

by Zacks Equity Research

QIAGEN's (QGEN) progress in test menu expansion, prospects in molecular diagnostics and strong solvency bode well.

AngioDynamics (ANGO) Q4 Earnings Top Estimates, Gross Margin Down

by Zacks Equity Research

AngioDynamics (ANGO) registers overall strong top-line results on a pro-forma basis in fourth-quarter fiscal 2024, driven by strength in the Med Tech business.

Catalent (CTLT) Expands Its Facility Capabilities in Germany

by Zacks Equity Research

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.

Integra's (IART) New Site to Produce Recalled Tissue Products

by Zacks Equity Research

Integra (IART) is set to recommence the manufacturing of PriMatrix and SurgiMend at its new facility in Braintree, MA.

Should You Keep Chemed (CHE) Stock in Your Portfolio Now?

by Zacks Equity Research

Chemed's (CHE) robust VITAS business and strong financial stability raise investors' optimism.

Here's Why Globus Medical (GMED) is a Strong Growth Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Globus Medical, Inc. (GMED) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Globus Medical (GMED) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

GMED vs. SONVY: Which Stock Is the Better Value Option?

by Zacks Equity Research

GMED vs. SONVY: Which Stock Is the Better Value Option?

Here's Why Globus Medical (GMED) is a Strong Value Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Why Globus Medical (GMED) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Globus Medical (GMED) Up 7.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why Globus Medical (GMED) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED) led by strong musculoskeletal prospects and raised guidance.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Globus Medical (GMED) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Globus Medical (GMED) outperforms the industry due to its stellar quarterly performance and impactful launches.

Here's Why Globus Medical (GMED) is a Strong Momentum Stock

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

GMED or PEN: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GMED vs. PEN: Which Stock Is the Better Value Option?